Moomoo AI 已提取核心訊息
Adial Pharmaceuticals, Inc. has announced a prospectus for the potential offering of up to $100,000,000 in securities, which may include common stock, preferred stock, debt securities, warrants, or units. The securities may be offered from time to time in various transactions at fixed prices, prevailing market prices, or negotiated prices. The specific terms of any offering, such as the names of underwriters, dealers, or agents, purchase price, and net proceeds, will be detailed in future prospectus supplements. The company's common stock is listed on the Nasdaq Capital Market under the symbol 'ADIL.' As of January 19, 2024, the last reported sale price of Adial's common stock was $1.275 per share. The company has not sold any shares of common stock under General Instruction I.B.6 to Form S-3 in the twelve months preceding the date of the prospectus. Investing in the securities involves risks, which are detailed under the heading 'Risk Factors' in the prospectus.
Adial Pharmaceuticals, Inc. has announced a prospectus for the potential offering of up to $100,000,000 in securities, which may include common stock, preferred stock, debt securities, warrants, or units. The securities may be offered from time to time in various transactions at fixed prices, prevailing market prices, or negotiated prices. The specific terms of any offering, such as the names of underwriters, dealers, or agents, purchase price, and net proceeds, will be detailed in future prospectus supplements. The company's common stock is listed on the Nasdaq Capital Market under the symbol 'ADIL.' As of January 19, 2024, the last reported sale price of Adial's common stock was $1.275 per share. The company has not sold any shares of common stock under General Instruction I.B.6 to Form S-3 in the twelve months preceding the date of the prospectus. Investing in the securities involves risks, which are detailed under the heading 'Risk Factors' in the prospectus.
Adial Pharmicals, Inc.已經宣佈了可能發行高達1億美元的證券的招股說明書，其中可能包括普通股、優先股、債務證券、認股權證或單位。證券可以不時地以固定價格、現行市場價格或協議價格以各種交易形式發行。任何發行的具體條款，例如承銷商、交易商或代理商的名稱、收購價格和淨收益，將在未來的招股說明書補充文件中詳細說明。該公司的普通股在納斯達克資本市場上市，股票代碼爲 “ADIL”。截至2024年1月19日，阿迪亞爾上次公佈的普通股銷售價格爲每股1.275美元。在招股說明書發佈之日前的十二個月中，該公司沒有根據一般指令I.B.6向S-3出售任何普通股。投資證券涉及風險，在招股說明書的 “風險因素” 標題下詳細介紹了這些風險。
Adial Pharmicals, Inc.已經宣佈了可能發行高達1億美元的證券的招股說明書，其中可能包括普通股、優先股、債務證券、認股權證或單位。證券可以不時地以固定價格、現行市場價格或協議價格以各種交易形式發行。任何發行的具體條款，例如承銷商、交易商或代理商的名稱、收購價格和淨收益，將在未來的招股說明書補充文件中詳細說明。該公司的普通股在納斯達克資本市場上市，股票代碼爲 “ADIL”。截至2024年1月19日，阿迪亞爾上次公佈的普通股銷售價格爲每股1.275美元。在招股說明書發佈之日前的十二個月中，該公司沒有根據一般指令I.B.6向S-3出售任何普通股。投資證券涉及風險，在招股說明書的 “風險因素” 標題下詳細介紹了這些風險。
有用
沒用
